Catherine R. Marinac, Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Monoclonal Gammopathy of Undetermined Significance | 4 | 2024 | 177 | 1.330 |
Why?
|
Multiple Myeloma | 10 | 2024 | 5181 | 1.250 |
Why?
|
Actigraphy | 6 | 2019 | 488 | 0.920 |
Why?
|
Breast Neoplasms | 19 | 2019 | 20822 | 0.890 |
Why?
|
Exercise | 10 | 2019 | 5615 | 0.860 |
Why?
|
Fasting | 3 | 2016 | 1593 | 0.770 |
Why?
|
Sleep | 8 | 2019 | 4623 | 0.770 |
Why?
|
Motor Activity | 6 | 2017 | 2714 | 0.570 |
Why?
|
Light | 2 | 2019 | 1374 | 0.530 |
Why?
|
Body Mass Index | 8 | 2023 | 12720 | 0.530 |
Why?
|
Obesity | 11 | 2024 | 12745 | 0.510 |
Why?
|
Survivors | 5 | 2017 | 2291 | 0.450 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 1 | 2021 | 2282 | 0.400 |
Why?
|
Cognition | 4 | 2018 | 6770 | 0.380 |
Why?
|
Aspirin | 1 | 2021 | 3282 | 0.350 |
Why?
|
Activities of Daily Living | 2 | 2017 | 2418 | 0.320 |
Why?
|
Energy Intake | 2 | 2015 | 2148 | 0.320 |
Why?
|
Health Status Disparities | 1 | 2020 | 1797 | 0.310 |
Why?
|
Metformin | 3 | 2019 | 835 | 0.290 |
Why?
|
Insulin Resistance | 3 | 2017 | 3864 | 0.270 |
Why?
|
Health Promotion | 1 | 2017 | 2205 | 0.250 |
Why?
|
Rest | 3 | 2018 | 901 | 0.250 |
Why?
|
C-Reactive Protein | 5 | 2017 | 3778 | 0.250 |
Why?
|
Healthcare Disparities | 1 | 2020 | 3158 | 0.240 |
Why?
|
Circadian Rhythm | 5 | 2018 | 2624 | 0.220 |
Why?
|
Life Style | 5 | 2017 | 3835 | 0.200 |
Why?
|
Neoplasms, Plasma Cell | 1 | 2021 | 36 | 0.200 |
Why?
|
Waldenstrom Macroglobulinemia | 2 | 2021 | 1052 | 0.190 |
Why?
|
Middle Aged | 26 | 2021 | 213383 | 0.190 |
Why?
|
Leukemia, Myelomonocytic, Chronic | 1 | 2022 | 97 | 0.190 |
Why?
|
Nutrition Surveys | 3 | 2020 | 1660 | 0.190 |
Why?
|
Risk Factors | 11 | 2024 | 72290 | 0.180 |
Why?
|
Inflammation | 3 | 2022 | 10638 | 0.180 |
Why?
|
Female | 36 | 2023 | 380194 | 0.180 |
Why?
|
Proportional Hazards Models | 4 | 2021 | 12354 | 0.180 |
Why?
|
Paraproteinemias | 1 | 2022 | 246 | 0.170 |
Why?
|
Pilot Projects | 4 | 2019 | 8324 | 0.160 |
Why?
|
Humans | 45 | 2024 | 744343 | 0.160 |
Why?
|
Neoplasm Recurrence, Local | 1 | 2016 | 9239 | 0.160 |
Why?
|
Aged | 21 | 2022 | 163280 | 0.160 |
Why?
|
Weight Loss | 2 | 2019 | 2622 | 0.150 |
Why?
|
Overweight | 3 | 2019 | 2371 | 0.150 |
Why?
|
Neoplasms | 3 | 2023 | 21683 | 0.150 |
Why?
|
Self Report | 2 | 2019 | 3558 | 0.140 |
Why?
|
Self Efficacy | 2 | 2017 | 616 | 0.140 |
Why?
|
Photoperiod | 1 | 2016 | 136 | 0.130 |
Why?
|
Hypoglycemic Agents | 2 | 2019 | 2872 | 0.130 |
Why?
|
Internet | 2 | 2017 | 3064 | 0.120 |
Why?
|
Prospective Studies | 6 | 2023 | 53288 | 0.120 |
Why?
|
Follow-Up Studies | 6 | 2021 | 39050 | 0.120 |
Why?
|
Prognosis | 7 | 2021 | 29063 | 0.120 |
Why?
|
Adult | 15 | 2020 | 214055 | 0.110 |
Why?
|
Independent Living | 1 | 2017 | 568 | 0.110 |
Why?
|
Demography | 1 | 2017 | 1656 | 0.100 |
Why?
|
Myelodysplastic Syndromes | 1 | 2022 | 1352 | 0.100 |
Why?
|
Bone Marrow | 2 | 2019 | 2948 | 0.100 |
Why?
|
Eating | 1 | 2018 | 1536 | 0.100 |
Why?
|
Data Collection | 1 | 2020 | 3341 | 0.090 |
Why?
|
Risk | 3 | 2021 | 9687 | 0.090 |
Why?
|
Antibodies, Viral | 1 | 2021 | 3176 | 0.090 |
Why?
|
Incidence | 2 | 2019 | 20947 | 0.090 |
Why?
|
Immunoglobulin G | 1 | 2021 | 4560 | 0.090 |
Why?
|
Hematopoietic Stem Cells | 1 | 2022 | 3386 | 0.090 |
Why?
|
High-Throughput Nucleotide Sequencing | 1 | 2021 | 3597 | 0.080 |
Why?
|
Decision Support Techniques | 1 | 2019 | 1956 | 0.080 |
Why?
|
Neoplasm Staging | 3 | 2019 | 11031 | 0.080 |
Why?
|
Mutation | 3 | 2022 | 29786 | 0.080 |
Why?
|
Health Surveys | 2 | 2017 | 4037 | 0.080 |
Why?
|
Combined Modality Therapy | 2 | 2019 | 8642 | 0.080 |
Why?
|
Gene Expression Regulation, Neoplastic | 2 | 2021 | 8428 | 0.080 |
Why?
|
Male | 15 | 2023 | 350118 | 0.080 |
Why?
|
Asymptomatic Diseases | 2 | 2021 | 551 | 0.080 |
Why?
|
Cohort Studies | 4 | 2022 | 40561 | 0.070 |
Why?
|
United States | 5 | 2020 | 69872 | 0.070 |
Why?
|
Randomized Controlled Trials as Topic | 3 | 2019 | 9959 | 0.070 |
Why?
|
Geriatric Assessment | 1 | 2013 | 1372 | 0.070 |
Why?
|
Software | 1 | 2020 | 4443 | 0.070 |
Why?
|
Insulin | 2 | 2017 | 6580 | 0.070 |
Why?
|
Neuropsychological Tests | 2 | 2014 | 6993 | 0.060 |
Why?
|
Cross-Sectional Studies | 4 | 2018 | 25043 | 0.060 |
Why?
|
Blood Glucose | 2 | 2015 | 6256 | 0.060 |
Why?
|
Patient Selection | 1 | 2015 | 4215 | 0.060 |
Why?
|
Gene Expression Profiling | 1 | 2019 | 9438 | 0.060 |
Why?
|
Registries | 1 | 2019 | 8089 | 0.060 |
Why?
|
Time Factors | 4 | 2019 | 40075 | 0.060 |
Why?
|
Feeding Behavior | 1 | 2015 | 3188 | 0.050 |
Why?
|
Carcinoma | 1 | 2014 | 2375 | 0.050 |
Why?
|
Hematologic Tests | 1 | 2023 | 240 | 0.050 |
Why?
|
Survival Analysis | 3 | 2020 | 10252 | 0.050 |
Why?
|
Logistic Models | 2 | 2014 | 13408 | 0.050 |
Why?
|
Coronavirus Infections | 1 | 2020 | 3133 | 0.050 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 3240 | 0.050 |
Why?
|
Young Adult | 5 | 2019 | 56430 | 0.050 |
Why?
|
Diet | 1 | 2020 | 7939 | 0.050 |
Why?
|
Immunologic Tests | 1 | 2021 | 103 | 0.050 |
Why?
|
Fatty Acid-Binding Proteins | 1 | 2023 | 300 | 0.050 |
Why?
|
Models, Statistical | 1 | 2015 | 5102 | 0.050 |
Why?
|
Aged, 80 and over | 7 | 2022 | 57776 | 0.050 |
Why?
|
Cognition Disorders | 1 | 2014 | 4043 | 0.040 |
Why?
|
Pandemics | 1 | 2020 | 8388 | 0.040 |
Why?
|
Models, Immunological | 1 | 2021 | 527 | 0.040 |
Why?
|
Quality of Life | 2 | 2017 | 12804 | 0.040 |
Why?
|
beta 2-Microglobulin | 1 | 2019 | 315 | 0.040 |
Why?
|
Creatinine | 1 | 2023 | 1919 | 0.040 |
Why?
|
Diabetes Mellitus | 1 | 2016 | 5751 | 0.040 |
Why?
|
Cell Hypoxia | 1 | 2019 | 675 | 0.040 |
Why?
|
Immunocompromised Host | 1 | 2021 | 847 | 0.030 |
Why?
|
Biological Clocks | 1 | 2018 | 321 | 0.030 |
Why?
|
Postmenopause | 2 | 2015 | 2461 | 0.030 |
Why?
|
Survival Rate | 2 | 2021 | 12788 | 0.030 |
Why?
|
Iceland | 1 | 2016 | 183 | 0.030 |
Why?
|
Hip | 1 | 2017 | 257 | 0.030 |
Why?
|
Wrist | 1 | 2017 | 224 | 0.030 |
Why?
|
Myeloid Differentiation Factor 88 | 1 | 2019 | 571 | 0.030 |
Why?
|
Mass Spectrometry | 1 | 2022 | 2203 | 0.030 |
Why?
|
California | 1 | 2018 | 1402 | 0.030 |
Why?
|
Cell Cycle | 1 | 2023 | 2967 | 0.030 |
Why?
|
Immunoglobulin M | 1 | 2019 | 1537 | 0.030 |
Why?
|
Posture | 1 | 2017 | 958 | 0.030 |
Why?
|
Telephone | 1 | 2015 | 617 | 0.030 |
Why?
|
Running | 1 | 2017 | 480 | 0.030 |
Why?
|
Nurses | 1 | 2020 | 2461 | 0.020 |
Why?
|
Seasons | 1 | 2016 | 1493 | 0.020 |
Why?
|
Proteomics | 1 | 2023 | 3638 | 0.020 |
Why?
|
Algorithms | 2 | 2023 | 13881 | 0.020 |
Why?
|
Walking | 1 | 2017 | 1180 | 0.020 |
Why?
|
Early Detection of Cancer | 1 | 2023 | 3086 | 0.020 |
Why?
|
Disease-Free Survival | 1 | 2019 | 6895 | 0.020 |
Why?
|
Estradiol | 1 | 2015 | 2020 | 0.020 |
Why?
|
Risk Assessment | 2 | 2020 | 23338 | 0.020 |
Why?
|
Public Health | 1 | 2020 | 2603 | 0.020 |
Why?
|
Biopsy | 1 | 2019 | 6756 | 0.020 |
Why?
|
Boston | 1 | 2019 | 9313 | 0.020 |
Why?
|
Prevalence | 1 | 2022 | 15226 | 0.020 |
Why?
|
Linear Models | 1 | 2014 | 5952 | 0.010 |
Why?
|
Animals | 3 | 2023 | 168757 | 0.010 |
Why?
|
Energy Metabolism | 1 | 2015 | 2899 | 0.010 |
Why?
|
Models, Biological | 1 | 2020 | 9583 | 0.010 |
Why?
|
Health Behavior | 1 | 2015 | 2636 | 0.010 |
Why?
|
Predictive Value of Tests | 1 | 2019 | 15076 | 0.010 |
Why?
|
Aging | 1 | 2022 | 8664 | 0.010 |
Why?
|
Disease Progression | 1 | 2019 | 13284 | 0.010 |
Why?
|
Treatment Outcome | 2 | 2023 | 63114 | 0.010 |
Why?
|
Sex Factors | 1 | 2016 | 10397 | 0.010 |
Why?
|
Odds Ratio | 1 | 2014 | 9849 | 0.010 |
Why?
|
Comorbidity | 1 | 2016 | 10388 | 0.010 |
Why?
|
Adolescent | 2 | 2019 | 85781 | 0.010 |
Why?
|
Disease Models, Animal | 1 | 2015 | 18029 | 0.010 |
Why?
|
Mice | 1 | 2023 | 81183 | 0.010 |
Why?
|
Retrospective Studies | 1 | 2023 | 77449 | 0.010 |
Why?
|
Child | 1 | 2017 | 77709 | 0.010 |
Why?
|